Skip to main content
Log in

Why Do the Majority of Submissions for Bridging from a Prefilled Syringe to an Autoinjector Include Bioequivalence Studies in Order to Demonstrate Comparability?

  • Commentary
  • Published:
The AAPS Journal Aims and scope Submit manuscript

Abstract

A recent paper reviewed clinical studies intending to bridge a prefilled syringe (PFS) to an autoinjector (AI) based on regulatory submission packages sent to the FDA. An AI generally uses the identical PFS within the AI and the AI typically results in a more consistent injection than can be achieved with a PFS. It is noted that several studies submitted to the FDA did not demonstrate bioequivalence (BE) between the PFS and AI, yet the products were approved anyway. The author of this Commentary believes that formal BE studies should not be required for such bridging studies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Hu P, Wang J, Florian J, Shatzer K, Stevens AM, Gertz J, et al. Systematic review of device parameters and design of studies bridging biologic-device combination products using prefilled syringes and autoinjectors. AAPS J. 2020;22:52. https://doi.org/10.1208/s12248-020-0433-8.

    Article  CAS  PubMed  Google Scholar 

  2. Human Factors Studies and Related Clinical Study Considerations in Combination Product Design and Development, Draft Guidance for Industry and FDA Staff, February 2016. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/human-factors-studies-and-related-clinical-study-considerations-combination-product-design-and. Accessed 26 March 2020.

  3. Bridging for Drug-Device and Biologic-Device Combination Products, Guidance for Industry, FDA, December 2019. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/bridging-drug-device-and-biologic-device-combination-products. Accessed 26 March 2020.

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to William J. Lambert.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lambert, W.J. Why Do the Majority of Submissions for Bridging from a Prefilled Syringe to an Autoinjector Include Bioequivalence Studies in Order to Demonstrate Comparability?. AAPS J 22, 72 (2020). https://doi.org/10.1208/s12248-020-00453-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1208/s12248-020-00453-0

KEY WORDS

Navigation